DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Heinemann V, von Weikersthal EF, Decker T. et al.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol 2014;
15: 1065-1075
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.